On March 30, 2018, "Yizhuang News" published an exclusive interview with Ms. Liu Changru, Chairman of Haibu Medicine, in a half_page. The full text is as follows:
Liu Changru, along the way, with his heart, perseverance and unchanging initial intention, with a global perspective, firmly promotes the continuous development of chemical drug research and development, and brings Beijing Haibu Pharmaceutical Technology Co., Ltd. to a new stage of development. The company owns two wholly_owned subsidiaries, Beijing Haimeitong and Haimeiyuan, and participates in Shandong Confucius Pharmaceutical Co., Ltd. in research and development of anti_tumor, depression, cardiovascular and cerebrovascular, digestive system, respiratory medicine and other fields. He has applied for more than 10 invention patents, obtained more than 10 new drug certificates and production approvals, and more than 40 drug clinical trial approvals. He was rated as “National High_tech Enterprise” and “Beijing Science and Technology Research and Development Organization”. The company was new in early 2016. The three boards were listed and listed in the capital injection of the Xinjiang Wuwu Oasis Equity Investment Partnership and the well_known investment institution Shenzhen Tongchuang Weiye in 2016 and 2017 respectively.
Ignorance and fearlessness
In front of Liu Changru is always smiling and full of affinity, close to the staff, it feels like a big sister next door, the affinity, peace of mind may be related to the experience of entrepreneurship.
"In 2006, just after the Spring Festival, I went to find a house everywhere. I chose the 309 of Block B of the Innovation Building in the Development Zone, which is now the third floor synthesis laboratory." Liu Changru recalled. Because she had less money in her hands, she talked with the property party several times and finally negotiated 5 yuan per square meter of rent per day.
"I thought that I saved a renovation fee, which is quite good." Haibu started with more than 300 square meters of space, and the rent can save 5,000 yuan a year, plus the previous company just moved away, blue The foyer, the empty hall and the several partitioned rooms, even the extensive decoration is saved.
In March of that year, even if the company opened, Liu Changru and a dozen young people who were “ignorant and fearless” took advantage of the future and hopes – HOPE= Haibu, discussing patents, new projects, and experimental plans. And approval strategy.
Soon after the company opened, it caught up with the State Food and Drug Administration to rectify the disorder of drug registration and approval, the changes in laws and regulations, and the confusion of the major pharmaceutical companies in the industry on the future of new drug development, which made the company face a crisis. In the second half of 2007, in addition to several small projects under study that were just opened, I did not see any hope of receiving new contracts.
Liu Changru realized that if he didn't want to find another way to live, the company might "die".
"It's really because of anxiety and can't sleep at night." At that time, Liu Changru's thought was that he could not give up. Under her efforts, she learned that a pharmaceutical company has a raw material drug product that has been discontinued for many years and must undergo process improvement before it can be re_produced. The other party suggested that if Haibu can provide them with production technology and help them complete GMP certification, they can supply intermediates to them as suppliers.
Liu Changru realized that this is an opportunity for Haibu. If you use your own technological advantages to capture the production process of the API, you can bring hope to Haibu. Liu Changru immediately promised that Haibu will invest its own funds in research and development and take risks at its own risk.
Since then, under the leadership of Liu Changru, the organization of research and development personnel, meticulous design, trial and error, through the hard work of the technical staff, overcome a number of technical difficulties, more than 10 months, finally completed a new production process, and in the drug The factory trial production was successful.
On the National Day of 2008, Liu Changru set foot on an international flight to Frankfurt. He took a 200_dollar pocket money from a friend and went to the CPHI show in Europe. "I just want to see how others do the company? What does the market need? What can we offer? Where is the future of Haibu?" Just when the plane is about to take off, Liu Changru received a call from the company: the goods have been sent Go to the customer's warehouse.
Haibu "live" came over.
踌躇满志 Building a new platform for Haibu
After the "big test", Liu Changru firmly believes that China's pharmaceutical industry is still a sunrise industry full of opportunities. Drug research and development is the core driving force for the development of this industry. As long as we persist in diligently working hard in this field, there will be room for survival and Opportunities for development.
In the following two or three years, the national drug research and development regulatory policy became clear and the entire industry returned to life. At this stage, Haibu is constantly recruiting talents, expanding laboratories, adding new instruments, and stocking new products. During the period, Haibu participated in Confucius Pharmaceuticals, participated in the whole process from planning and design to completion and acceptance, until the new factory obtained the drug production license in October 2012, and several new products developed by Haibu for Confucius were also It has been reported to the National Drug Evaluation Center.
In addition to accepting the varieties commissioned by the client, Liu Changru also used the balance's own funds to develop and reserve a dozen new drugs.
Although he has achieved some achievements, Liu Changru has always felt a sense of crisis with his mentality and alertness. During the development of the company, Liu Changru communicated with relevant enterprise management experts and pioneers of entrepreneurial success, learned from them, took stock of the problems and shortcomings of Haibu in the past, and learned about the successful experiences and lessons learned by the model companies. Steps to comprehensively reform and reform the plan and path, decided to lead Haibu into the capital market. In March 2016, Haibu passed the examination and approval and successfully listed on the New Third Board.
On the day of listing, Liu Changru specially invited the company representatives to participate in the new three board listing ceremony. This ceremony also marks the transformation of Haibu into a company with sustainable development capabilities.
Beginning in July 2015, the State Food and Drug Administration has successively introduced a series of new policies and regulations. China's pharmaceutical industry has really started a new round of rectification, major governance, and major reshuffle from R&D, production to sales.
The New Deal is both a challenge and an opportunity for Liu Changru. Only by courageously facing it, Haibu will surely come up with a bright road in the field of pharmaceutical research and development. Subsequently, she made a decision on Haibu's immediate and complete termination of the three types of projects under the independent project, and reopened the research and development according to the new standard. At the same time, 2016 will be designated as “sea step quality improvement year and standard year.” Haibu’s business capabilities, management capabilities and organizational capabilities have spiraled upward.
Firm confidence, determined to develop more new drugs
In the eyes of outsiders, the prospect of chemical drugs without biological drugs is good, but in Liu Changru's view, chemical drugs will have room for development in the next 20 or 30 years.
Liu Changru said, "Now the country is vigorously promoting the research and development of generic drugs. The prospects are no problem, and it is very confident. Haibu Medicine will still focus on the fields of chemical drugs and generic drugs, and related patents are in the process of application."
Regarding the future, Liu Changru hopes to bring some products to market by 2020. To achieve these goals, the team must have the ability to accept and learn, and have the ability to adapt to change. Haibu still needs to maintain 80% of its personnel in research and development, and develops its stamina for the company. On the technical level, Haibu will always R&D and technology are at the core, introducing applications that include technologies such as artificial intelligence and computer_aided design.
With the continuous advancement of technology, information technology and means in the field of drug research and development have become increasingly mature. Recently, Haibu Medicine has built a new information center computer room, and expanded its network and data center infrastructure to lay a solid foundation for the information application in the next 5_10 years. The company has extensively collected, discovered, tried software and database systems in experimental design, computer_aided analysis and formulation research and development, and gradually applied it in practical work, actively adapting to the changes brought by technological advancement to the industry, with a view to improving the work of drug development. effectiveness.
For Liu Changru, the long_term development of the company must be based on new technologies, means and technical applications, and always maintain the spirit of innovation in order to promote the company's long_term development.
"There must be an open heart, able to accept new things, and can be cross_border in the pharmaceutical field." Liu Changru feels that he is a particularly ideal person, she hopes that Haibu can develop more new drugs to benefit. Humanity. "The road to be taken must be stable, but always with a self_transcending heart." Liu Changru said.